echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: 2022 American College of Rheumatology/European Association of Rheumatology Association classification criteria for eosinophilic granulomatosis with polyangiitis

    ARD: 2022 American College of Rheumatology/European Association of Rheumatology Association classification criteria for eosinophilic granulomatosis with polyangiitis

    • Last Update: 2022-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Objective
    : To develop and validate the revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) .


    Objective

    : To develop and validate the revised
    classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA) .


    Methods
    : Patients with vasculitis or comparative disease were recruited into an international cohort
    .


    Methods
    Patients with vasculitis or comparative disease were recruited into an international cohort
    .

    The study was conducted in five phases:

    The study was conducted in five phases:
    1. Identify Candidate Criteria Projects Using a Consensus Approach
    2. Prospective collection of candidates present at diagnosis
    3. Data-driven reduction of the number of candidate projects
    4. Panel reviews cases to determine reference diagnosis
    5. Score-based risk scores for disease classifications were derived in the development set using least absolute shrinkage and selection operator logistic regression, followed by validation of performance feature cases and comparisons in an independent set
      .
  • Identify Candidate Criteria Projects Using a Consensus Approach
  • Identify Candidate Criteria Projects Using a Consensus Approach
  • Prospective collection of candidates present at diagnosis
  • Prospective collection of candidates present at diagnosis
  • Data-driven reduction of the number of candidate projects
  • Data-driven reduction of the number of candidate projects
  • Panel reviews cases to determine reference diagnosis
  • Panel reviews cases to determine reference diagnosis
  • Score-based risk scores for disease classifications were derived in the development set using least absolute shrinkage and selection operator logistic regression, followed by validation of performance feature cases and comparisons in an independent set
    .
  • Score-based risk scores for disease classifications were derived in the development set using least absolute shrinkage and selection operator logistic regression, followed by validation of performance feature cases and comparisons in an independent set
    .


    Results
    : The development set for EGPA included 107 EGPA and 450 comparison cases .
    The validation set consisted of an additional 119 EGPAs and 437 comparators .
    From the 91 candidate items, regression analysis identified 11 EPGA items , 7 of which were retained .
    Final criteria and their weights are as follows: maximum eosinophil count ≥ 1 × 10 9 /L ( +5 ), obstructive airway disease ( +3 ), nasal polyps ( +3 ), cytoplasmic antineutrophil cytoplasm Antibody ( ANCA ) or anti-protease 3 ANCA positive (-3) , extravascular eosinophil-predominant inflammation (+2)



    , polyneuritis / motor neuropathy (+1) and hematuria (-1) not due to radiculopathy
    .
    After excluding vasculitis-like conditions,
    patients diagnosed with small-vessel or medium-vessel vasculitis can be classified as EGPA if the cumulative score is ≥ 6 points .
    When testing these criteria in the validation dataset, the sensitivity was 85% ( 95% CI 77% to 91% ) and the specificity was 99% ( 95% CI 98% to 100% ) .



    Results

    Results
    : The development set for EGPA included 107 EGPA and 450 comparison cases .
    The validation set consisted of an additional 119 EGPAs and 437 comparators .
    From the 91 candidate items, regression analysis identified 11 EPGA items , 7 of which were retained .
    Final criteria and their weights were as follows: maximum eosinophil count ≥ 1 × 10 9 /L 9 ( +5 ), obstructive airway disease ( +3 ), nasal polyps ( +3 ), cytoplasmic antineutrophils Plasma antibody ( ANCA ) or anti-protease 3 ANCA positive (-3)



    , extravascular eosinophil-dominated inflammation (+2) , polymononeuritis / motor neuropathy (+1) not due to radiculopathy, and hematuria (-1)
    .
    After excluding vasculitis-like conditions,
    patients diagnosed with small-vessel or medium-vessel vasculitis can be classified as EGPA if the cumulative score is ≥ 6 points .
    When testing these criteria in the validation dataset, the sensitivity was 85% ( 95% CI 77% to 91% ) and the specificity was 99% ( 95% CI 98% to 100% ) .



    Conclusions
    : The 2022 American College of Rheumatology / European Association of Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis exhibited strong performance characteristics and was validated for research use
    .


    Conclusions The
    2022 American College of Rheumatology / European Association of Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis exhibits strong performance characteristics and is validated for research use
    .

     

    Source: Grayson PC, Ponte C, Suppiah R DCVAS Study Group , et al .
    2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
    Annals of the Rheumatic Diseases  2022; 81: 309-314.

    Grayson PC, Ponte C, Suppiah R DCVAS Study Group , et al .
    2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
    , et al Annals of the Rheumatic Diseases  Annals of the Rheumatic Diseases  2022; 81: 309-314.
    81:

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.